SEARCH

SEARCH BY CITATION

References

  • 1
    Bateman D. Delineations of cutaneous disease. London: Longman, 1817.
  • 2
    Rasch C. Om et polymorft (erythematost, vesikulost og ekzematoidt) lysudslet. Hospitalstid 1900; 43: 478480.
  • 3
    Pao C, Norris PG, Corbett M, Hawk JLM. Polymorphic light eruption: prevalence in Australia and England. Br J Dermatol 1994; 130: 6264.
  • 4
    Morison WL, Stern RS. Polymorphous light eruption: a common reaction uncommonly recognized. Acta Dermatol Venereol 1982; 62: 237240.
  • 5
    Ros AM, Wennersten G. Current aspects of polymorphous light eruptions in Sweden. Photodermatology 1986; 3: 298302.
  • 6
    Berg M, Ros AM, Berne B. Ultraviolet A phototherapy and trimethylpsoralen UVA photochemotherapy in polymorphous light eruption – a controlled study. Photodermatol Photoimmunol Photomed 1994; 10: 139143.
  • 7
    Guarrera M, Micalizzi C, Rebora A. Heterogeneity of polymorphous light eruption: a study of 105 patients. Arch Dermatol 1993; 129: 10601061.
  • 8
    Jansen CT. The natural history of polymorphous light eruptions. Arch Dermatol 1979; 115: 165169.
  • 9
    Petzelbauer P, Binder M, Nikolakis P, et al. Severe sun sensitivity and the presence of antinuclear antibodies in patients with polymorphous light eruption-like lesions: a forme fruste of photosensitive lupus erythematosus? J Am Acad Dermatol 1992; 26: 6874.
  • 10
    Stratigos AJ, Antoniou C, Katsambas AD. Polymorphous light eruption. J Eur Acad Dermatol Venereol 2002; 16: 193206.
  • 11
    Norris PG, Morris J, McGibbon DM, Chu AC, Hawk JLM. Polymorphic light eruption: an immunopathological study of evolving lesion. Br J Dermatol 1989; 120: 173183.
  • 12
    Kolgen W, Van Weelden H, Den Hengst S, et al. CD11b+ cells and ultraviolet-B-resistant CD1a+ cells in skin of patients with polymorphous light eruption. J Invest Dermatol 1999; 113: 410.
  • 13
    Millard TP, Bataille V, Snieder H, Spector TD, McGregor JM. The heritability of polymorphic light eruption. J Invest Dermatol 2000; 115: 467470.
  • 14
    McGregor JM, Grabczynska S, Vaughan R, Hawk JL, Lewis CM. Genetic modeling of abnormal photosensitivity in families with polymorphic light eruption and actinic prurigo. J Invest Dermatol 2000; 115: 471476.
  • 15
    Leroy D, Dompmartin A, Faguer K, Michel M, Verneuil L. Polychromatic phototest as a prognostic tool for polymorphic light eruption. Photodermatol Photoimmunol Photomed 2000; 16: 161166.
  • 16
    Mastalier U, Kerl H, Wolf P. Clinical, laboratory, phototest and phototherapy findings in polymorphic light eruptions: a retrospective study of 133 patients. Eur J Dermatol 1998; 8: 554559.
  • 17
    Salomon N, Messer G, Dick D, Plewig G, Rocken M. Phototesting for polymorphic light eruption (PLE) with consecutive UVA1/UVB-irradiation. Photodermatol Photoimmunol Photomed 1997; 13: 7274.
  • 18
    Ling TC, Rhodes LE. The clinical findings and phototest results in polymorphic light eruption. AAD poster abstract, San Francisco, March 2003.
  • 19
    British Photodermatology Group. Photopatch testing – methods and indications. Br J Dermatol 1997; 136: 371376.
  • 20
    Robson J, Diffey BL. Textiles and sun protection. Photodermatol Photoimmunol Photomed 1990; 7: 3234.
  • 21
    Gies HP, Roy CR, Elliott G, Zongli W. Ultraviolet radiation protection factors for clothing. Health Phys 1994; 67: 131139.
  • 22
    Farr PM, Diffey BL. Adverse effects of sunscreens in photosensitive patients. Lancet 1989; 1: 429431.
  • 23
    Stege H, Budde M, Grether-Beck S, et al. Sunscreens with high SPF values are not equivalent in protection from UVA induced polymorphous light eruption. Eur J Dermatol 2002; 12: IVVI.
  • 24
    Proby C, Baker C, Morton O, Hawk JLM. New broad-spectrum sunscreen for Polymorphic Light Eruption. Lancet 1993; 341: 13471348.
  • 25
    Allas S, Lui H, Moyal D, Bissonnette R. Comparison of the ability of 2 sunscreens to protect against polymorphous light eruption induced by a UV-A/UV-B metal halide lamp. Arch Dermatol 1999; 135: 14211422.
  • 26
    Azurdia RM, Pagliaro JA, Diffey BL, Rhodes LE. Sunscreen application by photosensitive patients is inadequate for protection. Br J Dermatol 1999; 140: 255258.
  • 27
    Azurdia RM, Pagliaro JA, Rhodes LE. Sunscreen application technique in photosensitive patients: a quantitative assessment of the effect of education. Photodermatol Photoimmunol Photomed 2000; 16: 5356.
  • 28
    Green C, Norris PG, Hawk JL. Photoallergic contact dermatitis from oxybenzone aggravating polymorphic light eruption. Contact Dermatitis 1991; 24: 6263.
  • 29
    Ferguson J, Ibbotson S. The idiopathic photodermatoses. Semin Cutan Med Surg 1999; 18: 257273.
  • 30
    Man I, Dawe RS, Ibbotson SH, Ferguson J. Is topical steroid effective in polymorphic light eruption. Br J Dermatol 2000; 142 (Suppl 57): 112114.
  • 31
    Patel DC, Bellaney GJ, Seed PT, McGregor JM, Hawk JL. Efficacy of short-course oral prednisolone in polymorphic light eruption: a randomized controlled trial. Br J Dermatol 2000; 143: 828831.
  • 32
    Van Praag MCG, Boom BW, Vermeer BJ. Diagnosis and treatment of polymorphous light eruption. Int J Dermatol 1994; 33: 233239.
  • 33
    Krutmann J, Morita A. Mechanisms of ultraviolet (UV) B and UVA phototherapy. J Invest Dermatol Symp Proc 1999; 4: 7072.
  • 34
    Gschnait F, Honigsmann H, Brenner W, Fritsch P, Wolff K. Induction of UV light tolerance by PUVA in patients with polymorphous light eruption. Br J Dermatol 1978; 99: 293295.
  • 35
    Parrish JA, Le Vine MJ, Morison WL, Gonzalez E, Fitzpatrick TB. Comparison of PUVA and beta-carotene in the treatment of polymorphous light eruption. Br J Dermatol 1979; 100: 187191.
  • 36
    Jansen CT, Karvonen J, Malmiharju T. PUVA therapy for polymorphous light eruptions: comparison of systemic methoxsalen and topical trioxsalen regimens and evaluation of local protective mechanisms. Acta Dermatol Venereol 1982; 62: 317320.
  • 37
    Addo HA, Sharma SC. UVB phototherapy and photochemotherapy (PUVA) in the treatment of polymorphic light eruption and solar urticaria. Br J Dermatol 1987; 116: 539547.
  • 38
    Morison WL, Momtaz K, Mosher DB, Parrish JA. UV-B phototherapy in the prophylaxis of polymorphous light eruption. Br J Dermatol 1982; 106: 231233.
  • 39
    Murphy GM, Logan RA, Lovell CR, Morris RW, Hawk JL, Magnus IA. Prophylactic PUVA and UVB therapy in polymorphic light eruption – a controlled trial. Br J Dermatol 1987; 116: 531538.
  • 40
    Bilsland D, George SA, Gibbs NK, Aitchison T, Johnson BE, Ferguson J. A comparison of narrow band phototherapy (TL-01) and photochemotherapy (PUVA) in the management of polymorphic light eruption. Br J Dermatol 1993; 129: 708712.
  • 41
    Man I, Dawe RS, Ferguson J. Artificial hardening for polymorphic light eruption: practical points from ten years' experience. Photodermatol Photoimmunol Photomed 1999; 15: 9699.
  • 42
    Rucker BU, Haberle M, Koch HU, Bocionek P, Schriever KH, Hornstein OP. Ultraviolet light hardening in polymorphous light eruption–a controlled study comparing different emission spectra. Photodermatol Photoimmunol Photomed 1991; 8: 7378.
  • 43
    Ortel B, Tanew A, Wolff K, Honigsmann H. Polymorphous light eruption: action spectrum and photoprotection. J Am Acad Dermatol 1986; 14: 748753.
  • 44
    Molin L, Volden G. Treatment of polymorphous light eruption with PUVA and prednisolone. Photodermatology 1987; 4: 107108.
  • 45
    Stern RS, Lange R. Non-melanoma skin cancer occurring in patients treated with PUVA five to ten years after first treatment. J Invest Dermatol 1988; 91: 120124.
  • 46
    Stern RS, Liebman EJ, Vakeva L. Oral psoralen and ultraviolet-A light (PUVA) treatment of psoriasis and skin cancer PUVA. Follow-up Study. J Natl Cancer Inst 1998; 90: 12781284.
  • 47
    Stern RS, Nichols KT, Vakeva LH. Malignant melanoma in patients treated for psoriasis with methoxsalen (psoralen) and ultraviolet A radiation (PUVA). The PUVA Follow-Up Study. N Engl J Med 1997; 336: 10411045.
  • 48
    Stern RS. The risk of melanoma in association with long-term exposure to PUVA. J Am Acad Dermatol 2001; 44: 755761.
  • 49
    Lindelof B, Sigurgeirsson B, Tegner E, et al. PUVA and cancer: a large-scale epidemiological study. Lancet 1991; 338: 9193.
  • 50
    Stern RS, Vakeva LH. Noncutaneous malignant tumors in the PUVA follow-up study: 1975–1996. J Invest Dermatol 1997; 108: 897900.
  • 51
    Pasker-de Jong PC, Wielink G, Van Der Valk PG, Van Der Wilt GJ. Treatment with UV-B for psoriasis and nonmelanoma skin cancer: a systematic review of the literature. Arch Dermatol 1999; 135: 834840.
  • 52
    Slaper H, Schothorst AA, Van der Leun JC. Risk evaluation of UVB therapy for psoriasis: comparison of calculated risk for UVB therapy and observed risk in PUVA-treated patients. Photodermatology 1986; 3: 271283.
  • 53
    Stern RS, Laird N. The carcinogenic risk of treatments for severe psoriasis. Photochemotherapy follow-up study. Cancer 1994; 73: 27592764.
  • 54
    Wulf HC, Hansen AB, Bech-Thomsen N. Differences in narrow-band ultraviolet B and broad-spectrum ultraviolet photocarcinogenesis in lightly pigmented hairless mice. Photodermatol Photoimmunol Photomed 1994; 10: 192197.
  • 55
    Gibbs NK, Traynor NJ, MacKie RM, Campbell I, Johnson BE, Ferguson J. Phototumorigenic potential of broad-band (280–340 nm) and narrow-band (310–313 nm) phototherapy sources cannot be predicted by their edematogenic potential in hairless mouse skin. J Invest Dermatol 1995; 104: 359363.
  • 56
    Flindt-Hansen H, McFadden N, Eeg-Larsen T, Thune P. Effect of a new narrow-band UVB lamp on photocarcinogenesis in mice. Acta Dermatol Venereol 1991; 71: 245248.
  • 57
    Young AR. Carcinogenicity of UVB phototherapy assessed. Lancet 1995; 345: 14311432.
  • 58
    Norris PG, Hawk JL. Successful treatment of severe polymorphous light eruption with azathioprine. Arch Dermatol 1989; 125: 13771379.
  • 59
    Shipley DRV, Hewitt JB. Polymorphic light eruption treated with Cyclosporin. Br J Dermatol 2001; 144: 446447.
  • 60
    Cowey FK, Whitehouse MW. Biochemical properties of anti-inflammatory drugs. VII. Inhibition of proteolytic enzymes in connective tissue by chloroquine (resochin) and related antimalarial antirheumatic drugs. Biochem Pharmacol 1966; 15: 10711084.
  • 61
    Murphy GM, Hawk JL, Magnus IA. Hydroxychloroquine in polymorphic light eruption: a controlled trial with drug and visual sensitivity monitoring. Br J Dermatol 1987; 116: 379386.
  • 62
    Corbett MF, Hawk JLM, Herxheimer A, et al. Controlled therapeutic trials in polymorphic light eruption. Br J Dermatol 1982; 107: 571581.
  • 63
    Jones SK. Ocular toxicity and hydroxychloroquine: guidelines for screening. Br J Dermatol 1999; 140: 37.
  • 64
    The Royal College of Ophthalmologists. Ocular toxicity and hydroxychloroquine: guidelines for screening. London; 1998
  • 65
    Thune P. Chronic polymorphic light eruption. Particular wavebands and the effect of carotene therapy. Acta Dermatol Venereol 1976; 56: 127133.
  • 66
    Wennersten G, Swanbeck G. Treatment of light sensitivity with carotenoids. Serum concentrations and light protection. Acta Dermatol Venereol 1974; 54: 491499.
  • 67
    Jansen CT. Beta-carotene treatment of polymorphous light eruptions. Dermatologica 1974; 149: 363373.
  • 68
    Mathews-Roth MM, Pathak MA, Fitzpatrick TB, Harber LH, Kass EH. Beta carotene therapy for erythropoietic protoporphyria and other photosensitivity diseases. Arch Dermatol 1977; 113: 12291232.
  • 69
    Nordlund JJ, Klaus SN, Mathews-Roth MM, Pathak MA. New therapy for polymorphous light eruption. Arch Dermatol 1973; 108: 710712.
  • 70
    Jansen CT. Oral carotenoid treatment in polymorphous light eruption: a cross-over comparison with oxychloroquine and placebo. Photodermatology 1985; 2: 166169.
  • 71
    Neumann R, Rappold E, Pohl-Markl H. Treatment of polymorphous light eruption with nicotinamide: a pilot study. Br J Dermatol 1986; 115: 7780.
  • 72
    Ortel B, Wechdorn D, Tanew A, Honigsmann H. Effect of nicotinamide on the phototest reaction in polymorphous light eruption. Br J Dermatol 1988; 118: 669673.
  • 73
    Norris PG, Hawk JL. Polymorphic light eruption. Photodermatol Photoimmunol Photomed 1990; 7: 186191.
  • 74
    Holzle E, Plewig G, Von Kries R, Lehmann P. Polymorphous light eruption. J Invest Dermatol 1987; 88 (3 Suppl): 32s38s.
  • 75
    Gonzalez E, Gonzalez S. Drug photosensitivity, idiopathic photodermatoses, and sunscreens. J Am Acad Dermatol 1996; 35: 871885.
  • 76
    Saul A, Flores O, Novales J. Polymorphous light eruption: treatment with thalidomide. Australas J Dermatol 1976; 17: 217218.
  • 77
    Birt AR, Davis RA. Hereditary polymorphic light eruption of American Indians. Int J Dermatol 1975; 14: 105111.
  • 78
    Tseng S, Pak G, Washenik K, Pomeranz MK, Shupack JL. Rediscovering Thalidomide: a review of its mechanism of action, side effects, and potential uses. J Am Acad Dermatol 1996; 35: 969979.
  • 79
    Rhodes LE, Durham BH, Fraser WD, Friedmann PS. Dietary fish oil reduces basal and ultraviolet B-generated PGE2 levels in skin and increases the threshold to provocation of polymorphic light eruption. J Invest Dermatol 1995; 105: 532535.
  • 80
    Rhodes LE, Shahbakhti H, Azurdia RM, et al. Effect of eicosapentaenoic acid, an omega-3 polyunsaturated fatty acid, on UVR-related cancer risk in humans. An assessment of early genotoxic markers. Carcinogenesis 2003; 24: 919925.
  • 81
    Rhodes LE, O'Farrell S, Jackson MJ, Friedmann PS. Dietary fish-oil supplementation in humans reduces ultraviolet B-induced erythemal responses but increases epidermal lipid peroxidation. J Invest Dermatol 1994; 103: 151154.
  • 82
    Pupe A, Moison R, De Haes P, et al. Eicosapentaenoic acid, a n-3 polyunsaturated fatty acid, differentially modulates TNFα, IL-1β, IL-6 and PGE2 expression in UVB-irradiated human keratinocytes. J Invest Dermatol 2002; 118: 692698.
  • 83
    Hadshiew I, Stab F, Untiedt S, Bohnsack K, Rippke F, Holzle E. Effects of topically applied antioxidants in experimentally provoked polymorphous light eruption. Dermatology 1997; 195: 362368.
  • 84
    Rippke F, Wendt G, Bohnsack K, et al. Results of photoprovocation and field studies on the efficacy of a novel topically applied antioxidant in polymorphous light eruption. J Dermatol Treat 2001; 12: 38.
  • 85
    Eberlein-Konig B, Fesq H, Abeck D, Pryzbilla B, Placzek M, Ring J. Systemic vitamin C and vitamin E do not prevent photoprovocation test reactions in polymorphous light eruption. Photodermatol Photoimmunol Photomed 2000; 16: 5052.
  • 86
    Przybilla B, Heppeler M, Ruzicka T. Preventive effect of an E. coli-filtrate (Colibiogen) in polymorphous light eruption. Br J Dermatol 1989; 121: 229233.
  • 87
    Leonard F, Morel M, Kalis B, et al. Psoralen plus ultraviolet A in the prophylactic treatment of benign summer light eruption. Photodermatol Photoimmunol Photomed 1991; 8: 9598.